Piramal Enterprises launch portable diagnostic device

The device that tests for 20 clinical parameters has been received well with 387 instruments being sold within just 45 days of the test marketing launch

piramal-enterprises

Piramal Enterprises' diagnostic division recently announced the launch of "QDx Instacheck" -Right-here-Right-now. It is touted to be a first-of-its-kind portable diagnostic device that is specifically designed to perform 20 clinical parameters and deliver quantitative results within 3 - 15 minutes. It covers wide therapeutic areas including cardiovascular disease, hormonal imbalance, emergency care, diabetes, oncology, infections, pregnancy and infertility management.

This portable and affordable device is considered to deliver quantitative test results with high accuracy. The device is virtually maintenance free and can be operated very easily with minimal training requirements. QDx Instacheck is particularly useful for doctors' clinics, emergency care units (such as ICU, CCU), hospitals, pathological labs, IVF centres, ambulance services, pharmaceutical companies and NGOs engaged in healthcare services.

Commenting on the launch Mr. Vijay Shah, Executive Director and Chief Operating Officer, Piramal Enterprises said, "It is our endeavour to empower the medical community such as gynaecologists, cardiologists, diabetologists, general physicians, pathological labs to perform critical tests Right-here-Right-now with minimum investment and lowest operating expenses and finally making treatment decisions faster. The launch of QDx Instacheck is in line with our division's vision of bringing affordable instant diagnostic solution through our point-of-care product range. This 1.3 kg portable device is the first-of-its-kind revolutionary instant diagnostic device in the Indian market that is poised to change traditional diagnostic methods to instant diagnosis."

QDx Instacheck has been commercially test marketed from January to March 2013 across various parts of India through our field force and over 250 authorised distributors. The formal launch of the product is scheduled in April 2013. A record of 387 instruments was sold in just 45 days from test marketing launch.

2 Comment Comment 1 - 1 of 1
comment

Jose 10 April 2013 at 06:52 AM

Oui, K ,dans l temps,j ai connu un photographe qui mais, ici, esyases donc les douches e9cossaises: c est souverain! Et puis au lieu de stresser, arreates donc ton char, prends ton jet(ame8nes-nous ton innnnnimitable TART AL POM -ave9 lassen-) avant de repartir en navette spaciale pour nous envoyer encore d autres infos side9rales.-Babs-:pour les ceux qui savent.

Reply

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

BusinessWire India.com - Healthcare & biotechnology

Bwi-logo

New Study Assesses the Utility of Masimo PVi® Monitoring During Colorectal

Tuesday, 28 Feb 2017   |   Masimo

Business Wire India Masimo (NASDAQ: MASI) announced the findings of a recent study conducted on low-risk

GSMA Launches Big Data for Social Good Initiative

Monday, 27 Feb 2017   |   GSMA

Business Wire India Today at Mobile World Congress, the GSMA launched the “Big Data for Social Good”

Kabir Bedi Named Brand Ambassador for Sightsavers

Monday, 27 Feb 2017   |   Sightsavers

Business Wire IndiaSightsavers, a leading global development organization working in over 30 countries

BusinessWire India.com - Pharmaceutical

Bwi-logo

New global survey results show: 2 out of 3 patients said they were involved

Tuesday, 28 Feb 2017   |   Boehringer Ingelheim

Business Wire India When agreeing on an appropriate treatment, 30% of involved patients said further

New Study Assesses the Utility of Masimo PVi® Monitoring During Colorectal

Tuesday, 28 Feb 2017   |   Masimo

Business Wire India Masimo (NASDAQ: MASI) announced the findings of a recent study conducted on low-risk

BusinessWire India.com - Medical Devices

Bwi-logo

New global survey results show: 2 out of 3 patients said they were involved

Tuesday, 28 Feb 2017   |   Boehringer Ingelheim

Business Wire India When agreeing on an appropriate treatment, 30% of involved patients said further

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email

X